Migalastat hydrochloride

Research use only, not for human use.

Migalastat hydrochloride (GR181413A) is an orally available, potent and competitive inhibitor of alpha-galactosidase A.

Migalastat hydrochloride (GR181413A) is a potent and competitive inhibitor of α-galactosidase A (α-Gal A) with an IC50 of 0.04 μM for human α-Gal A.

Cell Viability AssayCell Line:EHK cells mutated α-Gal A Concentration:10 μM Incubation Time:9 days Result:Reduced Gb3 accumulation and lysosome volume.

Animal Model:Male nontransgenic (Non-Tg) C57BL/6 mice; transgenic mice expressing human mutant R301Q α-Gal A (TgM), α-Gal A knockout mice (KO), mice express human R301Q α-Gal A in a null background (TgM/KO) Dosage:3 mg/kg Administration: Oral gavage; every day for 4 weeks Result:Reduced Globotriaosylceramide (Gb3) storage remarkably in kidney of mice.

——

Others

Other Targets

Others

——

——

75172-81-5

199.63

C6H14ClNO4

>98% (HPLC)

In Vitro:?H2O : ≥ 200 mg/mL (1001.85 mM)

Cl.OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O

——

(-20℃)

With Ice Pack

≥ 2 years